Similarly, Descovy for PrEP achieved record market share, with sales increasing 20% year-over-year to $701 million. The following slide illustrates the market leadership of these key HIV products: A ...
Gilead Sciences Inc (NASDAQ:GILD) presented its third-quarter 2025 financial results on October 30, reporting solid performance driven by its HIV franchise and new product launches. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results